BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

261 related articles for article (PubMed ID: 25039280)

  • 1. Dynamics of vitamin K antagonist and new oral anticoagulants use in atrial fibrillation: a Danish drug utilization study.
    Pottegård A; Poulsen BK; Larsen MD; Hallas J
    J Thromb Haemost; 2014 Sep; 12(9):1413-8. PubMed ID: 25039280
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Shifting from vitamin K antagonists to non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation: predictors, patterns and temporal trends.
    Shiyovich A; Shalev V; Chodick G; Tirosh M; Katz A; Klar MM; Shuvy M; Pereg D; Minha S
    BMC Cardiovasc Disord; 2021 Oct; 21(1):493. PubMed ID: 34645389
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical events preceding switching and discontinuation of oral anticoagulant treatment in patients with atrial fibrillation.
    Hellfritzsch M; Grove EL; Husted SE; Rasmussen L; Poulsen BK; Johnsen SP; Hallas J; Pottegård A
    Europace; 2017 Jul; 19(7):1091-1095. PubMed ID: 28641379
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment Changes among Users of Non-Vitamin K Antagonist Oral Anticoagulants in Atrial Fibrillation.
    Hellfritzsch M; Husted SE; Grove EL; Rasmussen L; Poulsen BK; Johnsen SP; Hallas J; Pottegård A
    Basic Clin Pharmacol Toxicol; 2017 Feb; 120(2):187-194. PubMed ID: 27580086
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Non-persistence risk and health care resource utilization of Italian patients with non-valvular atrial fibrillation.
    Cataldo N; Pegoraro V; Ripellino C; Bertasi V; Di Turi R; Pastorello M; Gambera M
    Recenti Prog Med; 2018 Feb; 109(2):113-121. PubMed ID: 29493635
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical Characteristics And Health Care Resources In Patients Treated With Oral Anticoagulants: Evidences From Italian Administrative Databases.
    Degli Esposti L; Andretta M; Di Pasquale G; Gambera M; Saragoni S; Perrone V; Buda S
    Vasc Health Risk Manag; 2019; 15():429-437. PubMed ID: 31632047
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Quality of life and patient satisfaction in patients with atrial fibrillation on stable vitamin K antagonist treatment or switched to a non-vitamin K antagonist oral anticoagulant during a 1-year follow-up: A PREFER in AF Registry substudy.
    De Caterina R; Brüggenjürgen B; Darius H; Köhler S; Lucerna M; Pecen L; Renda G; Schilling RJ; Schliephacke T; Zamorano JL; Le Heuzey JY; Kirchhof P
    Arch Cardiovasc Dis; 2018 Feb; 111(2):74-84. PubMed ID: 28942115
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adherence with oral anticoagulation in non-valvular atrial fibrillation: a comparison of vitamin K antagonists and non-vitamin K antagonists.
    Sørensen R; Jamie Nielsen B; Langtved Pallisgaard J; Ji-Young Lee C; Torp-Pedersen C
    Eur Heart J Cardiovasc Pharmacother; 2017 Jul; 3(3):151-156. PubMed ID: 28158553
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antithrombotic therapy use in patients with atrial fibrillation before the era of non-vitamin K antagonist oral anticoagulants: the Global Registry on Long-Term Oral Antithrombotic Treatment in Patients with Atrial Fibrillation (GLORIA-AF) Phase I cohort.
    Huisman MV; Ma CS; Diener HC; Dubner SJ; Halperin JL; Rothman KJ; Teutsch C; Schoof N; Kleine E; Bartels DB; Lip GY;
    Europace; 2016 Sep; 18(9):1308-18. PubMed ID: 27335063
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Trends in the prescription of novel oral anticoagulants in UK primary care.
    Loo SY; Dell'Aniello S; Huiart L; Renoux C
    Br J Clin Pharmacol; 2017 Sep; 83(9):2096-2106. PubMed ID: 28390065
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Use of oral anticoagulants in combination with antiplatelet(s) in atrial fibrillation.
    Sindet-Pedersen C; Staerk L; Lamberts M; Gerds TA; Berger JS; Nissen Bonde A; Langtved Pallisgaard J; Hansen ML; Torp-Pedersen C; Gislason GH; Bjerring Olesen J
    Heart; 2018 Jun; 104(11):912-920. PubMed ID: 29092916
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Trends in antithrombotic drug use and adherence to non-vitamin K oral anticoagulants in the Netherlands.
    Hanemaaijer S; Sodihardjo F; Horikx A; Wensing M; De Smet PA; Bouvy ML; Teichert M
    Int J Clin Pharm; 2015 Dec; 37(6):1128-35. PubMed ID: 26243531
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differences in knowledge among patients with atrial fibrillation receiving non-vitamin K antagonist oral anticoagulants and vitamin K antagonists.
    Konieczyńska M; Sobieraj E; Bryk AH; Dębski M; Polak M; Podolec P; Małecka B; Pająk A; Desteghe L; Heidbuchel H; Undas A
    Kardiol Pol; 2018; 76(7):1089-1096. PubMed ID: 29528483
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oral anticoagulation therapy use in patients with atrial fibrillation after the introduction of non-vitamin K antagonist oral anticoagulants: findings from the French healthcare databases, 2011-2016.
    Maura G; Billionnet C; Drouin J; Weill A; Neumann A; Pariente A
    BMJ Open; 2019 Apr; 9(4):e026645. PubMed ID: 31005934
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of Treatment Persistence with Dabigatran or Rivaroxaban versus Vitamin K Antagonist Oral Anticoagulants in Atrial Fibrillation Patients: A Competing Risk Analysis in the French National Health Care Databases.
    Maura G; Billionnet C; Alla F; Gagne JJ; Pariente A
    Pharmacotherapy; 2018 Jan; 38(1):6-18. PubMed ID: 29028119
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Patterns of long-term use of non-vitamin K antagonist oral anticoagulants for non-valvular atrial fibrillation: Quebec observational study.
    Douros A; Renoux C; Coulombe J; Suissa S
    Pharmacoepidemiol Drug Saf; 2017 Dec; 26(12):1546-1554. PubMed ID: 28984052
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Apixaban for prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation in France: The PAROS cross-sectional study of routine clinical practice.
    Falissard B; Picard F; Mahe I; Hanon O; Touzé E; Danchin N; Lamy FX; Ricci L; Steg PG
    Arch Cardiovasc Dis; 2019; 112(6-7):400-409. PubMed ID: 31014991
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Drug Utilization Pattern of Oral Anticoagulants in Patients with Atrial Fibrillation: A Nationwide Population-Based Study in Korea.
    Lee MY; Han S; Bang OY; On YK; Jang SW; Han S; Ryu J; Park YJ; Kang S; Suh HS; Kim YH
    Adv Ther; 2022 Jul; 39(7):3112-3130. PubMed ID: 35524839
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effectiveness and Safety of Non-vitamin K Antagonist Oral Anticoagulants for Atrial Fibrillation and Venous Thromboembolism: A Systematic Review and Meta-analyses.
    Almutairi AR; Zhou L; Gellad WF; Lee JK; Slack MK; Martin JR; Lo-Ciganic WH
    Clin Ther; 2017 Jul; 39(7):1456-1478.e36. PubMed ID: 28668628
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effectiveness and safety of oral anticoagulation with non-vitamin K antagonists compared to well-managed vitamin K antagonists in naïve patients with non-valvular atrial fibrillation: Propensity score matched cohort study.
    Denas G; Gennaro N; Ferroni E; Fedeli U; Saugo M; Zoppellaro G; Padayattil Jose S; Costa G; Corti MC; Andretta M; Pengo V
    Int J Cardiol; 2017 Dec; 249():198-203. PubMed ID: 28935464
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.